{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:21:06Z","timestamp":1791861666230,"version":"4.3.4"},"reference-count":86,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.cmi.2019.04.013","type":"journal-article","created":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T23:32:30Z","timestamp":1555543950000},"page":"943-950","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":225,"title":["Management of carbapenem-resistant Enterobacteriaceae infections"],"prefix":"10.1016","volume":"25","author":[{"given":"E.","family":"Durante-Mangoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Andini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Zampino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2019.04.013_bib1","unstructured":"Centers for Disease Control and Prevention. Facility guidance for control of carbapenem-resistant Enterobacteriaceae (CRE). November 2015 update \u2013 CRE toolkit. Available at: https:\/\/www.cdc.gov\/hai\/organisms\/cre\/cre-toolkit\/index.html."},{"key":"10.1016\/j.cmi.2019.04.013_bib2","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00642-17","article-title":"Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant Enterobacteriaceae","volume":"61","author":"Haidar","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.04.013_bib3","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1128\/CMR.05035-11","article-title":"Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions","volume":"25","author":"Tzouvelekis","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2019.04.013_bib4","unstructured":"EUCAST. Available at: http:\/\/www.eucast.org\/clinical_breakpoints\/. Accessed 20 September 2018."},{"key":"10.1016\/j.cmi.2019.04.013_bib5","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1055\/s-0035-1544208","article-title":"Carbapenemase-producing Enterobacteriaceae","volume":"36","author":"Doi","year":"2015","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.cmi.2019.04.013_bib6","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13756-017-0259-z","article-title":"Infection prevention and control measures and tools for the prevention of entry of carbapenem-resistant Enterobacteriaceae into healthcare settings: guidance from the European Centre for Disease Prevention and Control","volume":"6","author":"Magiorakos","year":"2017","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.cmi.2019.04.013_bib7","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3201\/eid1710.110655","article-title":"Global spread of carbapenemase-producing Enterobacteriaceae","volume":"17","author":"Nordmann","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.cmi.2019.04.013_bib8","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/1469-0691.12719","article-title":"The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide","volume":"20","author":"Nordmann","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.04.013_bib9","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1517\/14656566.2016.1145658","article-title":"Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply \"precision medicine\" to antimicrobial chemotherapy?","volume":"17","author":"Perez","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.cmi.2019.04.013_bib10","series-title":"Surveillance of antimicrobial resistance in Europe 2016","author":"European Centre for Disease Prevention and Control","year":"2017"},{"key":"10.1016\/j.cmi.2019.04.013_bib11","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/phar.1622","article-title":"The \u03b2-lactams strike back: ceftazidime-avibactam","volume":"35","author":"Zasowski","year":"2015","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cmi.2019.04.013_bib12","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2019.04.013_bib13","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a Phase 3 randomized trial program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.04.013_bib14","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2019.04.013_bib15","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.04.013_bib16","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1021\/acs.jmedchem.5b00127","article-title":"Discovery of a cyclic boronic acid \u03b2-lactamase inhibitor (RPX7009) with utility vs. class A serine carbapenemases","volume":"58","author":"Hecker","year":"2015","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.cmi.2019.04.013_bib17","article-title":"Pharmacokinetics\/pharmacodynamics of vaborbactam, a novel \u03b2-lactamase inhibitor, in combination with meropenem","volume":"63","author":"Griffith","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.04.013_bib18","article-title":"Phase 1 study of the safety, tolerability, and pharmacokinetics of vaborbactam and meropenem alone and in combination following single and multiple doses in healthy adult subjects","volume":"62","author":"Rubino","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.04.013_bib19","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2018.0438","article-title":"Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I Randomized Clinical Trial","volume":"319","author":"Kaye","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2019.04.013_bib20","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00174-18","article-title":"Relebactam is a potent inhibitor of the KPC-2 \u03b2-lactamase and restores imipenem susceptibility in KPC-producing Enterobacteriaceae","volume":"62","author":"Papp-Wallace","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.04.013_bib21","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1128\/AAC.00633-16","article-title":"Phase 2, Dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection","volume":"60","author":"Lucasti","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.04.013_bib22","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01411-17","article-title":"Intrapulmonary pharmacokinetics of relebactam, a novel \u03b2-lactamase inhibitor, dosed in combination with imipenem-cilastatin in healthy subjects","volume":"62","author":"Rizk","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.04.013_bib23","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1093\/jac\/dkx139","article-title":"Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem\/cilastatin plus relebactam with imipenem\/cilastatin alone in patients with complicated urinary tract infections","volume":"72","author":"Sims","year":"2017","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.04.013_bib24","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00079-17","article-title":"Treatment of infections caused by extended-spectrum-\u03b2-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae","volume":"31","author":"Rodr\u00edguez-Ba\u00f1o","year":"2018","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2019.04.013_bib25","doi-asserted-by":"crossref","first-page":"5893","DOI":"10.1128\/AAC.00387-11","article-title":"Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem resistant Klebsiella pneumoniae from urine","volume":"55","author":"Satlin","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.04.013_bib26","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1128\/AAC.01314-10","article-title":"Optimization of aminoglycoside therapy","volume":"55","author":"Drusano","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.04.013_bib27","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/jac\/dkq408","article-title":"Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates","volume":"66","author":"Livermore","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.04.013_bib28","first-page":"191","article-title":"Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece","volume":"24","author":"Galani","year":"2012","journal-title":"J\u00a0Chemother"},{"key":"10.1016\/j.cmi.2019.04.013_bib29","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJMoa1801467","article-title":"Once-daily plazomicin for complicated urinary tract infections","volume":"380","author":"Wagenlehner","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2019.04.013_bib30","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.cmi.2018.07.020","article-title":"Developing a new antibiotic for extensively drug-resistant pathogens: the case of plazomicin","volume":"24","author":"Theuretzbacher","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.04.013_bib31","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.cmi.2017.02.023","article-title":"Clinical considerations for optimal use of the polymyxins: a focus on agent selection and dosing","volume":"23","author":"Pogue","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.04.013_bib32","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.ijantimicag.2016.09.010","article-title":"Pharmacokinetics\/pharmacodynamics of colistin and polymyxin B: are we there yet?","volume":"48","author":"Tran","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.04.013_bib33","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/phar.2209","article-title":"International consensus guidelines for the optimal use of the polymyxins","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cmi.2019.04.013_bib34","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1128\/AAC.01361-08","article-title":"Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria","volume":"53","author":"Plachouras","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.04.013_bib35","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.cmi.2016.08.004","article-title":"Acute kidney injury during colistin therapy: a prospective study in patients with extensively-drug resistant Acinetobacter baumannii infections","volume":"22","author":"Durante-Mangoni","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.04.013_bib36","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.diagmicrobio.2018.04.012","volume":"92","author":"Sader","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2019.04.013_bib37","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1093\/ofid\/ofy293","article-title":"Antimicrobial susceptibility of Acinetobacter calcoaceticus-Acinetobacter baumannii complex and Stenotrophomonas maltophilia clinical isolates: results from the SENTRY Antimicrobial Surveillance Program (1997\u20132016)","volume":"6","author":"Gales","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2019.04.013_bib38","doi-asserted-by":"crossref","first-page":"E23","DOI":"10.1111\/1469-0691.12070","article-title":"High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality","volume":"19","author":"Capone","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.04.013_bib39","doi-asserted-by":"crossref","first-page":"e3126","DOI":"10.1097\/MD.0000000000003126","article-title":"Tigecycline treatment for carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis","volume":"95","author":"Ni","year":"2016","journal-title":"Medicine (Balt)"},{"key":"10.1016\/j.cmi.2019.04.013_bib40","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.diagmicrobio.2015.06.011","article-title":"Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from 18 European nations: results from the SENTRY surveillance program (2010\u20132013)","volume":"83","author":"Sader","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2019.04.013_bib41","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1128\/JCM.02037-12","article-title":"Comparative evaluation of tigecycline susceptibility testing methods for expanded-spectrum cephalosporin- and carbapenem-resistant gram-negative pathogens","volume":"50","author":"Zarkotou","year":"2012","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2019.04.013_bib42","unstructured":"US FDA. Available at: https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm369580.htm Accessed 20 September 2018."},{"key":"10.1016\/j.cmi.2019.04.013_bib43","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijantimicag.2018.02.011","article-title":"Monotherapy with high-dose once-daily tigecycline is highly effective against Acinetobacter baumanii and other multidrug-resistant (MDR) Gram-negative bacilli (GNB)","volume":"52","author":"Cunha","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.04.013_bib44","doi-asserted-by":"crossref","first-page":"R90","DOI":"10.1186\/cc13858","article-title":"High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria","volume":"18","author":"De Pascale","year":"2014","journal-title":"Crit Care"},{"key":"10.1016\/j.cmi.2019.04.013_bib45","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/00365548.2013.861608","article-title":"Tigecycline therapy for infections due to carbapenemase-producing Klebsiella pneumoniae in critically ill patients","volume":"46","author":"Balandin Moreno","year":"2014","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.cmi.2019.04.013_bib46","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3109\/23744235.2015.1049659","article-title":"Tigecycline for carbapenem-resistant Klebsiella pneumoniae infections in the intensive care unit","volume":"47","author":"Vardakas","year":"2015","journal-title":"Infect Dis (Lond)"},{"key":"10.1016\/j.cmi.2019.04.013_bib47","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ijantimicag.2014.07.014","article-title":"High-dose tigecycline-associated alterations in coagulation parameters in critically ill patients with severe infections","volume":"45","author":"Routsi","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.04.013_bib48","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1128\/CMR.00068-15","volume":"29","author":"Falagas","year":"2016","journal-title":"Fosfomycin Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2019.04.013_bib49","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ijantimicag.2016.02.001","article-title":"Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature","volume":"47","author":"Vardakas","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.04.013_bib50","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ijantimicag.2013.09.010","article-title":"Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria","volume":"43","author":"Pontikis","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.04.013_bib51","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1128\/AAC.02611-15","article-title":"Long-term fosfomycin-tromethamine oral therapy for difficult-to-treat chronic bacterial prostatitis","volume":"60","author":"Los-Arcos","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.04.013_bib52","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1093\/jac\/dkw178","article-title":"Treatment of MDR urinary tract infections with oral fosfomycin: a retrospective analysis","volume":"71","author":"Seroy","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.04.013_bib53","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1469-0691.2009.02921.x","article-title":"Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation","volume":"16","author":"Michalopoulos","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.04.013_bib54","doi-asserted-by":"crossref","first-page":"E72","DOI":"10.1111\/1469-0691.12091","article-title":"Bacteraemia due to OXA-48-carbapenemase-producing Enterobacteriaceae: a major clinical challenge","volume":"19","author":"Navarro-San Francisco","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.04.013_bib55","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/ja.2016.73","article-title":"In\u00a0vitro susceptibility of \u03b2-lactamase-producing carbapenem resistant Enterobacteriaceae (CRE) to eravacycline","volume":"69","author":"Zhang","year":"2016","journal-title":"J\u00a0Antibiot (Tokyo)"},{"key":"10.1016\/j.cmi.2019.04.013_bib56","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijantimicag.2018.10.007","volume":"53","author":"Kazmierczak","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.04.013_bib57","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","article-title":"Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE 1) Trial: a randomized clinical trial","volume":"152","author":"Solomkin","year":"2017","journal-title":"JAMA Surg"},{"key":"10.1016\/j.cmi.2019.04.013_bib58","article-title":"IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs. meropenem in the treatment of complicated intra-abdominal infections","author":"Solomkin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.04.013_bib59","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2019.04.013_bib60","first-page":"e01801","article-title":"ARGONAUT-I: activity of cefiderocol (S-649266), a siderophore cephalosporin, against Gram-negative bacteria, including carbapenem-resistant nonfermenters and Enterobacteriaceae with defined extended-spectrum \u03b2-lactamases and carbapenemases","volume":"63","author":"Jacobs","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.04.013_bib61","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1128\/AAC.06268-11","article-title":"Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens","volume":"56","author":"Qureshi","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.04.013_bib62","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/cid\/cis588","article-title":"Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy","volume":"55","author":"Tumbarello","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.04.013_bib63","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1128\/AAC.02166-13","article-title":"Carbapenemase producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems","volume":"58","author":"Daikos","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.04.013_bib64","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1093\/jac\/dkv086","article-title":"Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study","volume":"70","author":"Tumbarello","year":"2015","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.04.013_bib65","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s10096-017-2899-6","article-title":"Carbapenemase-producing Klebsiella pneumoniae bloodstream infection in critically ill patients: risk factors and predictors of mortality","volume":"36","author":"Papadimitriou-Olivgeris","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2019.04.013_bib66","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jac\/dkw377","article-title":"Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis","volume":"72","author":"Zusman","year":"2017","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.04.013_bib67","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1093\/jac\/dku168","article-title":"Combination therapy for carbapenem-resistant Gram-negative bacteria","volume":"69","author":"Paul","year":"2014","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.04.013_bib68","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1128\/AAC.01230-13","article-title":"Systematic review and meta-analysis of in\u00a0vitro synergy of polymyxins and carbapenems","volume":"57","author":"Zusman","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.04.013_bib69","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.cmi.2018.01.015","article-title":"Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals","volume":"24","author":"Papst","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.04.013_bib70","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S1473-3099(17)30228-1","article-title":"Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study","volume":"17","author":"Gutierrez-Gutierrez","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2019.04.013_bib71","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/ciw636","article-title":"Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections","volume":"63","author":"Shields","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.04.013_bib72","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00449-17","article-title":"Multicenter study of outcomes with ceftazidime-avibactam in patients with carbapenem-resistant Enterobacteriaceae infections","volume":"61","author":"King","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.04.013_bib73","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dky295","article-title":"Effectiveness of ceftazidime\/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae","author":"Sousa","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.04.013_bib74","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijid.2017.03.021","article-title":"Clinical efficacy of ceftazidime\/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients","volume":"59","author":"Cast\u00f3n","year":"2017","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2019.04.013_bib75","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ijantimicag.2018.01.016","article-title":"Clinical experience with ceftazidime\/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae","volume":"51","author":"Santevecchi","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.04.013_bib76","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/cid\/ciy492","article-title":"Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by KPC-producing Klebsiella pneumoniae","volume":"68","author":"Tumbarello","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.04.013_bib77","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00883-17","article-title":"Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.04.013_bib78","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01964-16","article-title":"Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms","volume":"61","author":"Temkin","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.04.013_bib79","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.04.013_bib80","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02497-17","article-title":"Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections","volume":"62","author":"Shields","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.04.013_bib81","doi-asserted-by":"crossref","first-page":"e9961","DOI":"10.1097\/MD.0000000000009961","article-title":"High-dose tigecycline for the treatment of nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections: a retrospective cohort study","volume":"97","author":"Geng","year":"2018","journal-title":"Medicine (Balt)"},{"key":"10.1016\/j.cmi.2019.04.013_bib82","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","article-title":"Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial","volume":"18","author":"Paul","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2019.04.013_bib83","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1056\/NEJMc1807634","article-title":"Plazomicin for infections caused by carbapenem-resistant Enterobacteriaceae","volume":"380","author":"McKinnell","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2019.04.013_bib84","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II Randomized Clinical Trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.cmi.2019.04.013_bib85","series-title":"Poster O0427 presented at the 28th ECCMID","article-title":"RESTORE-IMI 1: a multicenter, randomized, double-blind, comparator controlled trial comparing the efficacy and safety of imipenem\/relebactam versus colistin plus imipenem in patients with imipenem-non-susceptible bacterial infections","author":"Motsch","year":"2018"},{"key":"10.1016\/j.cmi.2019.04.013_bib86","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.cmi.2017.09.001","article-title":"New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?","volume":"23","author":"Wright","year":"2017","journal-title":"Clin Microbiol Infect"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X19301843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X19301843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:22:48Z","timestamp":1761117768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X19301843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":86,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S1198743X19301843"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2019.04.013","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of carbapenem-resistant Enterobacteriaceae infections","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2019.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}